Author

Dughan J. Ahimovic

Weill Cornell MedicineORCID 0000-0002-5849-335XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cell type annotation· 2 Assay:ChIP-seq· 2 Approach:experimental assay· 2 Organism:mouse· 2 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

Michael J. BaleiD· 3 shared Steven Zvi JosefowicziD· 3 shared Andrew W. DamaniD· 2 shared Mythili KetavarapuiD· 2 shared Rachel E. NieciD· 2 shared Adam R. MarksiD· 1 shared Alejandro Martin-TrujilloiD· 1 shared Alexander M. TsankoviD· 1 shared

Activity by Year

2024-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

Michael J. BaleORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Signaling induced biophysical disruption of repressed chromatin domains drives immune cell fate

Alexia Martínez de Paz, Christopher R. Chin, Mythili Ketavarapu, Yuchen Sun, Matthew R. Marunde, Jeremy T.-H. Chang, Laiba F Khan, John Cohen, Rui Yang, Michael J. Bale, Andrew W. Daman, Vigneshwari E. Kumar, Chenyang Jiang, Dughan J. Ahimovic, Mark Owyong, , Steven Zvi Josefowicz

The paper identifies H3 serine 28 phosphorylation as a mechanism driving chromatin derepression and immune cell fate transitions by disrupting repressive chromatin domains.

bioRxiv · Dec 11, 2025 · PreprintImmunology

Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumors

Samarth Hegde, Bruno Giotti, Brian Y. Soong, László Halász, Jessica Le Bérichel, Maximilian M. Schaefer, Benoit Kloeckner, Raphaël Mattiuz, Matthew D. Park, Assaf Magen, Adam R. Marks, Meriem Belabed, Pauline Hamon, Theodore M. Chin, Leanna Troncoso, , Miriam Mérad

The paper identifies NRF2-driven myeloid progenitor dysregulation that sustains immunosuppressive macrophages in tumors, showing NRF2 inhibition reduces their survival and enhances antitumor immunity.

Nature · Sep 10, 2025Peer-reviewedImmunology

Microbial cancer immunotherapy reprograms hematopoietic stem cells to enhance anti-tumor immunity

Andrew W. Daman, Anthony C. Antonelli, Gil Redelman‐Sidi, Lucinda Paddock, Shireen Khayat, Mythili Ketavarapu, Jin‐Gyu Cheong, Leonardo F. Jurado, Anna Benjamin, Song Jiang, Dughan J. Ahimovic, Victoria R. Lawless, Michael J. Bale, Oleg Loutochin, Victor A. McPherson, , Michael S. Glickman

This study shows that bladder BCG immunotherapy reprograms hematopoietic stem cells to enhance anti-tumor immunity in mice and humans.

Cancer Cell · Mar 21, 2024Peer-reviewedImmunology